Securities code: 000078 securities abbreviation: Shenzhen Neptunus Bioengineering Co.Ltd(000078) Announcement No.: 2022-002 Shenzhen Neptunus Bioengineering Co.Ltd(000078)
Annual performance forecast for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 to December 31, 2021
2. Expected operating performance: losses turn into profits, rising and falling in the same direction
(1) Expected performance in the reporting period
The current reporting period of the project is the same period of last year
Profit attributable to listed companies: 60 million yuan – 85 million yuan, loss: 288.5313 million yuan, net profit of shareholders
Net profit after deducting non recurring loss: 47 million yuan – 72 million yuan, loss: 332.7784 million yuan
Basic earnings per share: 0.0218 yuan / share – 0.0309 yuan / share loss: 0.105 yuan / share
2、 Communication with accounting firms
The relevant data of this performance forecast is the preliminary calculation result of the company’s financial department and has not been audited by an accounting firm. However, the company has made pre communication with the annual audit accounting firm on major matters related to the performance forecast. There is no significant difference between the company and the accounting firm in the performance forecast in the reporting period. The specific data shall be subject to the audit results.
3、 Description of main reasons for performance changes
During the reporting period, the net profit attributable to the shareholders of the listed company turned losses into profits mainly due to the following reasons: 1. During the reporting period, the covid-19 pneumonia epidemic in China was controlled, the public medical institutions basically resumed the reception, the distribution business of the company’s subordinate operating units to the public medical institutions returned to normal, and the company’s operating revenue increased compared with the same period of last year.
2. Provision for impairment of goodwill. During the reporting period, the epidemic of covid-19 pneumonia in China was controlled, public medical institutions resumed reception, the distribution business of the company’s subordinate business units to public medical institutions returned to normal, and the operating revenue of the company’s subsidiaries increased compared with the same period of last year. According to the relevant requirements of accounting supervision risk tip No. 8 – goodwill impairment and accounting standards for Business Enterprises No. 8 – asset impairment, the company conducted a preliminary impairment test on the goodwill formed by the acquisition of subsidiaries in the early stage, It is estimated that the amount of goodwill impairment withdrawn in the current period is 17 million yuan – 21 million yuan (the actual amount withdrawn shall be determined according to the goodwill impairment test and evaluation report issued by the evaluation institution). The provision for goodwill impairment withdrawn in the current reporting period is lower than that in the same period of last year, resulting in the company’s performance turning loss into profit in the current reporting period.
4、 Risk tips
This performance forecast is the preliminary calculation result of the company’s financial department, and the specific financial data will be disclosed in detail in the 2021 annual report. The company will make timely information disclosure in strict accordance with relevant regulations and requirements. Please pay attention to investment risks.
It is hereby announced.
Shenzhen Neptunus Bioengineering Co.Ltd(000078) board of directors
January 27, 2002
